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Introduction
Patients with chronic obstructive pulmonary disease (COPD) 
are at high risk of developing community-acquired pneumonia 
(CAP). We recently completed a secondary analysis of the 
University of Louisville Pneumonia Study [1] and documented 
an annual incidence of 9,369 patients with CAP per 100,000 
COPD population [2]. We estimated that 506,953 adults with 
COPD are hospitalized due to CAP in the United States every 
year [2]. This incidence rate is almost 18-fold greater that the 
incidence rate of CAP patients without COPD [2]. 
Three interrelated factors play a role in the pathogenesis of CAP 
in COPD patients: 1) abnormalities in the lung microbiome, 
2) abnormalities in the lung immunity, and 3) the virulence of 
the pathogen causing CAP (Figure 1). In this opinion piece we 
would like to speculate that alterations of the lung microbiome 
may be a critical factor in the increased susceptibility of CAP in 
COPD patients. 
Lung Microbiome
The differences in the lung microbiome from a normal lung to 
a lung of a patient with COPD are depicted in Figure 2. In the 
normal lung, the alveolar microbiome contains a low number 
of organisms with a high diversity of bacterial communities 
(Figure 2A). The microbiome in the normal lung is constituted 
primarily of anaerobic organisms, with predominance of the 
phylum Bacteroidetes [3]. Some microorganisms are living 
freely in the alveolar space, in a planktonic form, but half 
of the bacterial communities are attached to alveolar cells 
[4]. The alveolar flora may impede the multiplication of new 
arriving pathogenic bacteria by several mechanisms. A normal 
microbiome may compete for attachment sites on alveolar cells, 
may compete for essential bacterial nutrients, or may produce 
antibacterial substances to inhibit the growth of pathogenic 
bacteria.
In the COPD patient there are alterations in the number 
and types of organisms present in the lung microbiome, a 
phenomenon known as dysbiosis [5]. In the COPD lung the 
microbiome contains high number of microorganisms, with 
a low diversity of bacterial communities. It is likely that 
several of these organisms are living in cell-associated biofilm 
communities (Figure 2B). The abnormal alveolar microbiome 
of COPD patients may be unable to impede the multiplication 
of invading pathogens, enhancing susceptibility to pneumonia.
Lung Immunity
Macrophages, surfactant, and oxygen levels play a role in 
alveolar immunity. Alveolar macrophage phagocytosis of 
new organisms arriving to the alveoli is a primary step in the 
prevention of pneumonia [6]. Surfactant acts as a component of 
the alveolar host defenses by binding to the surface of pathogens 
arriving to the alveoli [7]. Opsonization of bacteria by surfactant 
facilitates phagocytosis by alveolar macrophages. Normal 
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Figure 1 Interplay of lung microbiome, lung immunity and pneumonia 
pathogen in the pathogenesis of CAP in COPD. 
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oxygen level is important in alveolar immunity since hypoxemia 
is associated to local inflammation and immune dysfunction [8]. 
Alveolar dysbiosis in COPD patients may enhance susceptibility 
to pneumonia by producing abnormal macrophage function, 
surfactant degradation and low oxygen levels.
Pneumonia Pathogen
As the severity of COPD progresses over time, the risk for the 
patient to develop CAP increases, and the number of pathogens 
able to cause CAP expand (Figure 3). The patient with mild to 
moderate COPD will be at risk of infection with the pathogens 
causing CAP in non-COPD patients with the addition of beta-
lactamase producing bacteria such as Haemophilus influenzae, 
Moraxella catarrhalis, and Staphylococcus aureus. In 
patients with severe COPD the list of likely organisms able to 
cause CAP will extend to Gram-negative Enterobacteriaceae 
such as Klebsiella pneumoniae or Escherichia coli as well as 
Gram-negative non-fermenting bacilli such as Pseudomonas 
aeruginosa [2,9]. According to the local epidemiology, 
methicillin-resistant Staphylococcus aureus (MRSA) may also 
cause CAP in patients with severe COPD. 
CAP Pathogenesis
The primary model of pneumonia pathogenesis in COPD 
patients will start with the pneumonia pathogens arriving to 
the alveoli in greater number due to more frequent episodes of 
microaspiration. Once in the alveoli the pneumonia pathogens 
will overcome the abnormal alveolar microbiota as well as the 
abnormal alveolar immunity. The uncontrolled multiplication 
of the pathogen will cause the development of pneumonia.
Another possible model of pathogenesis of CAP in COPD 
patients may include a combination of alveolar multiplication 
of new pathogenic bacteria arriving to the alveoli associated to 
uncontrolled multiplication of some of the species present in the 
alveolar microbiota. In this type of pathogenesis, the etiology 
of pneumonia will be polymicrobial, with a combination of 
invading pathogenic bacteria plus bacteria normally present in 
the alveoli.  
A final model of pathogenesis may involve the uncontrolled 
multiplication of some of the bacteria already present in 
the alveolar microbiota. In this case, the etiologic agent of 
pneumonia will be bacteria that typically constitute the alveoli 
normal flora. This scenario may explain why in several COPD 
patients with CAP an etiologic agent is not identified, since 
alveolar microbiome bacteria cannot be isolated using regular 
culture techniques.
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Figure 3 Likely pathogens causing CAP in COPD patients according to 
severity of COPD.
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Conclusion
The alveolar microbiome plays an important role in maintaining 
a normal alveolar immunity. In patients with COPD, the 
dysbiosis of alveolar microbiota may alter several elements 
of alveolar immunity. In this opinion piece we speculate that 
alveolar dysbiosis may be a primary reason for the increased 
susceptibility to CAP in COPD patients.
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